NASDAQ$TRDA
Entrada Therapeutics Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Headline financials
Revenue & EPS history
Entrada Therapeutics · Revenue · Quarterly
$875K
Q1 2026-95.7%vs Q1 2025
Revenue by segment
Entrada Therapeutics · $43.7M total across 1 segment · Q3 2023
- Collaboration revenue$43.7M—100.0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports
-0.8%
Avg return
Earnings day
-0.8%
Avg return
5 days after
-4.5%
Avg return
30 days after
50%
11 / 22 earnings
Positive
+16.0%
Q4 2021
Best reaction
-57.1%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -57.1% | -55.7% | -60.3% | |
| Q4 2025 | +6.5% | -1.1% | -0.4% | |
| Q3 2025 | -2.2% | +1.9% | +49.9% | |
| Q1 2025 | -0.2% | -5.3% | -6.5% | |
| Q4 2024 | -0.3% | -8.6% | -20.5% | |
| Q3 2024 | +5.0% | +11.5% | +14.4% | |
| Q2 2024 | +11.3% | +16.3% | +4.6% | |
| Q1 2024 | +4.1% | +6.2% | +17.0% | |
| Q4 2023 | +5.4% | +7.2% | +11.8% | |
| Q3 2023 | +7.9% | +6.3% | -14.6% | |
| Q2 2023 | +9.8% | +17.7% | +5.0% | |
| Q1 2023 | -0.3% | +5.0% | +22.6% | |
| Q4 2022 | +1.4% | +14.5% | +31.4% | |
| Q3 2022 | -12.9% | -13.7% | -19.6% | |
| Q2 2022 | +0.2% | -1.7% | +18.3% | |
| Q1 2022 | +4.9% | +8.5% | +67.5% | |
| Q4 2021 | +16.0% | +20.4% | -1.0% | |
| Q4 2020 | -3.6% | -9.3% | -43.6% | |
| Q3 2020 | -3.6% | -9.3% | -43.6% | |
| Q2 2021 | -3.6% | -9.3% | -43.6% | |
| Q3 2021 | -3.6% | -9.3% | -43.6% | |
| Q1 2021 | -3.6% | -9.3% | -43.6% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro